CDSCO, January 28, 2026, The CDSCO’s 2026 updated list standardizes the authorized testing facilities for In Vitro Diagnostic (IVD) reagents and kits in India. Manufacturers and importers can now leverage an expanded network of laboratories to ensure compliance with the Medical Devices Rules, 2017, accelerating market entry and improving submission quality. The CDSCO has released its updated list of Laboratories for conducting Performance Evaluation of In-Vitro Diagnostic Medical Devices. This comprehensive document provides vital guidance for manufacturers and importers regarding where their diagnostic products must be evaluated for safety and efficacy. Understanding the specific labs assigned to each device category is essential for successful regulatory regularization in India.
PERFORMANCE EVALUATION OF IVD MEDICAL DEVICES : KEY UPDATES IN THE CDSCO 2026 LIST
The updated notification consolidates testing facilities across 22 categories of IVD reagents and kits, including:
- Expanded Laboratory Network: Integration of multiple AIIMS branches (Bathinda, Raebareli, Patna, and Bhubaneswar) to decentralize the testing process.
- Specialized Testing for High-Risk Kits: Dedicated facilities for HIV, HBV, HCV, and Syphilis evaluation, led by the National Institute of Biologicals (NIB) and ICMR-NARI.
- Viral Research Infrastructure: A robust network of VRDLs for the evaluation of SARS-CoV-2, Influenza, Dengue, and Chikungunya kits.
- Specific Categories for Chronic Diseases: Detailed lab assignments for Cancer markers, Tuberculosis, and Congenital disorder markers.
IN VITRO DIAGNOSTIC IMPACT ON THE INDIAN HEALTH SECTOR
The standardized list improves predictability and transparency in the regulatory review process:
- Accelerated Approval Times: By providing a wider choice of regional labs, manufacturers can reduce testing bottlenecks.
- Improved Accuracy: Clear nodal officer details and contact information help companies prevent technical errors in their submissions.
- Standardized Quality: Ensures all IVDs used in the Indian health sector undergo rigorous evaluation by premier national institutes.
HOW COMPANIES CAN COMPLY
To align with the updated requirements, companies should:
- Match Product to Category: Identify the exact category (1 through 22) their device falls under to select the correct testing facility.
- Engage with Nodal Officers: Use the provided email and contact details to verify sample requirements and evaluation timelines.
- Verify Regional Availability: Select labs based on geographical proximity to reduce logistics risks for temperature-sensitive reagents.
- Stay Updated: Monitor CDSCO notifications to ensure compliance with any future revisions to the laboratory network.